Mass Tort brief
Bellwethers Advance Across Phthalate, Suboxone, and Tech Dockets
Federal judges set trial dates and strip statutory shields as major corporate mass tort dockets advance into 2027.
Mass Tort
L'Oréal faces its first hair relaxer jury in September 2027 — ending months of stalled talks and forcing cosmetics giants toward formal settlement terms.
BackgroundChemical hair relaxers use alkaline agents and industrial plasticizers to straighten textured hair by breaking internal protein bonds. Long-term epidemiological research from the National Institutes of Health subsequently linked regular use of these endocrine-disrupting formulations to higher rates of uterine and endometrial cancer.
- The multidistrict litigation consolidates over 12,100 active federal lawsuits representing 32,000 claimants across the country, creating enormous litigation exposure for cosmetic manufacturers.
- Plaintiffs allege manufacturers marketed products containing phthalates and toxic compounds for decades without warning consumers, despite internal awareness of reproductive health risks.
- A locked trial date strips defense counsel of delay tactics, forcing L'Oréal, Revlon, and secondary defendants to either prepare for public juries or negotiate structured payouts.
Mass Tort
A Massachusetts jury cleared J&J of causing a fatal mesothelioma case — offering the company critical trial leverage as federal talc dockets resume.
BackgroundJohnson & Johnson faces tens of thousands of claims alleging asbestos contamination in its legacy cosmetic talc caused ovarian cancer and mesothelioma. Multiple corporate bankruptcy attempts designed to corral and settle the liabilities were dismissed by federal courts.
- The defense verdict bolsters J&J's courtroom standing just as thousands of talc cases return to active trial dockets nationwide.
- In federal MDL No. 2738 in New Jersey, Judge Michael Shipp is conducting strict Rule 702 scientific screening over 70,000 ovarian cancer lawsuits.
- Plaintiffs' attorneys continue targeting friendlier state court dockets where corporate causation defenses face looser evidentiary thresholds.
Mass Tort
Suboxone claims crossed 20,000 cases — putting Indivior under intense pressure to resolve acidic film liabilities before federal bellwether trials start.
BackgroundSuboxone sublingual film dissolves buprenorphine under the tongue to treat opioid use disorder and reduce withdrawal symptoms. Its acidic chemical formulation strips protective tooth enamel, prompting the FDA to mandate an official dental decay warning in 2022.
- Plaintiffs claim Indivior knew for over a decade that sublingual film dissolved enamel but concealed the hazard from prescribing doctors and dentists.
- Core discovery depositions for prescribing doctors and treating dental specialists must wrap by January 15, 2027, setting up a compressed timeline for trial selection.
- Legal analysts project Indivior's settlement liability could reach hundreds of millions of dollars if bellwether trials demonstrate corporate failure to warn.
Mass Tort
Over 6,400 women joined the Depo-Provera docket — setting up a high-stakes scientific hearing that will determine whether Pfizer's warning delays reach a jury.
BackgroundDepo-Provera is an injectable progestin birth control medication administered once every three months to prevent pregnancy. Medical studies published in 2024 revealed that prolonged exposure to high-dose medroxyprogesterone acetate multiplies the risk of developing intracranial meningioma tumors.
- Court orders set a November 30, 2026 registration deadline for claimants who underwent surgery or radiation for confirmed meningioma brain tumors.
- Pfizer's legal defense relies on challenging whether epidemiological data proves direct biological causation rather than a non-causal statistical correlation.
- Plaintiffs allege Pfizer warned European patients about meningioma risks years before updating safety labels on packaging distributed across the United States.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
